Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522777 | 1.00 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL522778 | 1.00 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL30402374 | 1.00 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL523001 | 0.93 | EGLN2 (0.70) | EGLN2EGLN1 | |
| SCHEMBL523000 | 0.93 | EGLN2 (0.70) | EGLN2EGLN1 | |
| SCHEMBL523565 | 0.92 | EGLN2 (0.58) | EGLN2EGLN1 | |
| SCHEMBL523441 | 0.92 | EGLN2 (0.58) | EGLN2EGLN1 | |
| SCHEMBL523564 | 0.92 | EGLN2 (0.58) | EGLN2EGLN1 | |
| SCHEMBL523442 | 0.92 | EGLN2 (0.58) | EGLN2EGLN1 | |
| SCHEMBL5141933 | 0.89 | EGLN2 (0.55) | EGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035000-A1 | HIF HYDROXYLASE INHIBITORS FOR TREATMENT OF ANEMIA OF CANCER | FIBROGEN, INC. (US) | 2009-03-18 | — | — | EP | claimed |
| WO-2007146438-A1 | HIF HYDROXYLASE INHIBITORS FOR TREATMENT OF ANEMIA OF CANCER | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-9775902-B2 | Compounds and methods for treatment of stroke | FIBROGEN, INC (US) | 2017-10-03 | — | — | US | disclosed |
| US-8530404-B2 | Compounds and methods for treatment of cancer | FIBROGEN, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110263644-A1 | Compounds and Methods for Treatment of Stroke | FIBROGEN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-1919463-B9 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20110015223-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100204269-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | FIBROGEN, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| EP-1919463-B1 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2010-06-09 | — | — | EP | disclosed |
| US-7713986-B2 | administering an enzyme inhibitor for inhibiting hypoxia inducible factor (HIF) hydroxylase activity; who is refractory to or is at risk for being refractory to recombinant human EPO therapy | FIBROGEN, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-2035000-A1 | HIF HYDROXYLASE INHIBITORS FOR TREATMENT OF ANEMIA OF CANCER | FIBROGEN, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1919463-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007146438-A1 | HIF HYDROXYLASE INHIBITORS FOR TREATMENT OF ANEMIA OF CANCER | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146425-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070292433-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070259960-A1 | Compounds and methods for treatment of stroke | FIBROGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070004627-A1 | Compounds and methods for treatment of cancer | FIBROGEN, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204269-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | EPOR, MCL1, HIF1AN | EGLN2 11/4885EGLN1 25/4885 |
| US-20110263644-A1 | Compounds and Methods for Treatment of Stroke | PLAT, SERPINE1, PLG | EGLN2 415/4885EGLN1 740/4885 |
| US-20070259960-A1 | Compounds and methods for treatment of stroke | PLAT, SERPINE1, PLG | EGLN2 415/4885EGLN1 740/4885 |
| US-20110015223-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | EGLN2 11/4885EGLN1 21/4885 |
| US-20070004627-A1 | Compounds and methods for treatment of cancer | TP53, MKI67, HDGF | EGLN2 39/4885EGLN1 98/4885 |
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | EGLN2 11/4885EGLN1 21/4885 |
| US-20070292433-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | EPOR, MCL1, HIF1AN | EGLN2 11/4885EGLN1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.